Download PDF
Semin Reprod Med 2010; 28(5): 351-359
DOI: 10.1055/s-0030-1262894
© Thieme Medical Publishers

Emerging Facade of Menopausal Hormone Therapy

Margaret Rees1
  • 1Reader in Reproductive Medicine, University of Oxford; Honorary Consultant in Medical Gynaecology; Visiting Professor, Faculty of Medicine, University of Glasgow; and Adjunct Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of Medicine and Dentistry of New Jersey
Further Information

Publication History

Publication Date:
15 September 2010 (online)

    Permissions and Reprints

ABSTRACT

Menopausal hormone therapy (HT) has been around for 70 years, and in the 1980s and 1990s was considered a universal panacea for women's problems from midlife onward. However, this concept was challenged by the results of the Women's Health Initiative (WHI) and the Million Women Study (MWS) that were first published in 2002 and 2003. Since the publication of these studies, prescriptions of HT have markedly declined and there have been many media scares. An unfortunate sequel was an extrapolation of the observations from women in their 50s and older to those with early ovarian failure. This article discusses the WHI and the MWS with a focus on differences between HT regimens including doses, formulations, and routes, timing, and duration of HT. It addresses practical issues such as strategies for stopping HT, and discusses bioidentical hormones. The specialist knowledge now required to deliver post-reproductive health service has led to considerations that menopause management should be now the responsibility of a specialist and not a general gynecologist.

KEYWORDS

Menopause - hormone therapy - estrogen - progestogen - aging

REFERENCES

  • 1 Wilson R A. Feminine Forever. New York, NY; Pocket Books 1968
    PubMedGoogle Scholar
  • 2 Wittes J, Barrett-Connor E, Braunwald E et al. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.  Clin Trials. 2007;  4(3) 218-234
    CrossrefPubMedGoogle Scholar
  • 3 Rossouw J E, Anderson G L, Prentice R L Writing Group for the Women's Health Initiative Investigators et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288(3) 321-333
    CrossrefPubMedGoogle Scholar
  • 4 Anderson G L, Limacher M, Assaf A R Women's Health Initiative Steering Committee et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.  JAMA. 2004;  291(14) 1701-1712
    CrossrefPubMedGoogle Scholar
  • 5 Beral V. Million Women Study Collaborators . Breast cancer and hormone-replacement therapy in the Million Women Study.  Lancet. 2003;  362(9382) 419-427
    CrossrefPubMedGoogle Scholar
  • 6 Shapiro S. Recent epidemiological evidence relevant to the clinical management of the menopause.  Climacteric. 2007;  10(Suppl 2) 2-15
    CrossrefPubMedGoogle Scholar
  • 7 Shapiro S. Explaining risk. A guide for health professionals.  Maturitas. 2009;  64(3) 143-144
    CrossrefPubMedGoogle Scholar
  • 8 Rochon P A, Gurwitz J H, Sykora K et al. Reader's guide to critical appraisal of cohort studies: 1. Role and design.  BMJ. 2005;  330(7496) 895-897
    CrossrefPubMedGoogle Scholar
  • 9 Jadad A R. Randomised Controlled Trials: A User's Guide. London, United Kingdom; BMJ Books 1998
    PubMedGoogle Scholar
  • 10 American Cancer Society .Breast Cancer Facts & Figures 2007–2008. Available at: http://www.cancer.org/downloads/STT/BCFF-Final.pdf Accessed October 8, 2009
    PubMedGoogle Scholar
  • 11 Chlebowski R T, Hendrix S L, Langer R D WHI Investigators et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.  JAMA. 2003;  289(24) 3243-3253
    CrossrefPubMedGoogle Scholar
  • 12 Manson J E, Hsia J, Johnson K C Women's Health Initiative Investigators et al. Estrogen plus progestin and the risk of coronary heart disease.  N Engl J Med. 2003;  349(6) 523-534
    CrossrefPubMedGoogle Scholar
  • 13 Hellgren M, Conard J, Norris L, Kluft C. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.  Maturitas. 2009;  62(3) 287-293
    CrossrefPubMedGoogle Scholar
  • 14 Hsia J, Langer R D, Manson J E Women's Health Initiative Investigators et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.  Arch Intern Med. 2006;  166(3) 357-365
    CrossrefPubMedGoogle Scholar
  • 15 Weiderpass E, Adami H O, Baron J A et al. Risk of endometrial cancer following estrogen replacement with and without progestins.  J Natl Cancer Inst. 1999;  91(13) 1131-1137
    CrossrefPubMedGoogle Scholar
  • 16 Lacey Jr J V, Leitzmann M F, Chang S C et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.  Cancer. 2007;  109(7) 1303-1311
    CrossrefPubMedGoogle Scholar
  • 17 Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994–1997.  Cancer Causes Control. 2001;  12(2) 111-115
    CrossrefPubMedGoogle Scholar
  • 18 Anderson G L, Judd H L, Kaunitz A M Women's Health Initiative Investigators et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.  JAMA. 2003;  290(13) 1739-1748
    CrossrefPubMedGoogle Scholar
  • 19 Weiderpass E, Baron J A, Adami H O et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study.  Lancet. 1999;  353(9167) 1824-1828
    CrossrefPubMedGoogle Scholar
  • 20 Canonico M, Plu-Bureau G, Lowe G D, Scarabin P Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.  BMJ. 2008;  336(7655) 1227-1231
    CrossrefPubMedGoogle Scholar
  • 21 Rossouw J E, Prentice R L, Manson J E et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.  JAMA. 2007;  297(13) 1465-1477
    CrossrefPubMedGoogle Scholar
  • 22 Grodstein F, Manson J E, Stampfer M J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation.  J Womens Health (Larchmt). 2006;  15(1) 35-44
    CrossrefPubMedGoogle Scholar
  • 23 Prentice R L, Manson J E, Langer R D et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.  Am J Epidemiol. 2009;  170(1) 12-23
    CrossrefPubMedGoogle Scholar
  • 24 Miller V M, Black D M, Brinton E A et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).  J Cardiovasc Transl Res. 2009;  2(3) 228-239
    CrossrefPubMedGoogle Scholar
  • 25 Zandi P P, Carlson M C, Plassman B L Cache County Memory Study Investigators et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study.  JAMA. 2002;  288(17) 2123-2129
    CrossrefPubMedGoogle Scholar
  • 26 Shumaker S A, Legault C, Rapp S R WHIMS Investigators et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.  JAMA. 2003;  289(20) 2651-2662
    CrossrefPubMedGoogle Scholar
  • 27 Shumaker S A, Legault C, Kuller L Women's Health Initiative Memory Study et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.  JAMA. 2004;  291(24) 2947-2958
    CrossrefPubMedGoogle Scholar
  • 28 Shuster L T, Rhodes D J, Gostout B S, Grossardt B R, Rocca W A. Premature menopause or early menopause: long-term health consequences.  Maturitas. 2010;  65(2) 161-166
    CrossrefPubMedGoogle Scholar
  • 29 Ewertz M, Mellemkjaer L, Poulsen A H et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study.  Br J Cancer. 2005;  92(7) 1293-1297
    CrossrefPubMedGoogle Scholar
  • 30 Rivera C M, Grossardt B R, Rhodes D J et al. Increased cardiovascular mortality after early bilateral oophorectomy.  Menopause. 2009;  16(1) 15-23
    CrossrefPubMedGoogle Scholar
  • 31 Politi M C, Schleinitz M D, Col N F. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis.  J Gen Intern Med. 2008;  23(9) 1507-1513
    CrossrefPubMedGoogle Scholar
  • 32 Col N F, Guthrie J R, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study.  Menopause. 2009;  16(3) 453-457
    CrossrefPubMedGoogle Scholar
  • 33 Al-Azzawi F, Barlow D, Hillard T, Studd J, Williamson J, Rees M. Writing Group on Osteoporosis for the British Menopause Society Council . Prevention and treatment of osteoporosis in women.  Menopause Int. 2007;  13(4) 178-181
    CrossrefPubMedGoogle Scholar
  • 34 Bagger Y Z, Tankó L B, Alexandersen P et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.  Bone. 2004;  34(4) 728-735
    CrossrefPubMedGoogle Scholar
  • 35 Gallagher J C, Sai A J. Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis.  Maturitas. 2010;  65(4) 301-307
    CrossrefPubMedGoogle Scholar
  • 36 Kanis J A, McCloskey E V, Johansson H, Strom O, Borgstrom F, Oden A. National Osteoporosis Guideline Group . Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK.  Osteoporos Int. 2008;  19(10) 1395-1408
    CrossrefPubMedGoogle Scholar
  • 37 Compston J, Cooper A, Cooper C National Osteoporosis Guideline Group (NOGG) et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.  Maturitas. 2009;  62(2) 105-108
    CrossrefPubMedGoogle Scholar
  • 38 Ockene J K, Barad D H, Cochrane B B et al. Symptom experience after discontinuing use of estrogen plus progestin.  JAMA. 2005;  294(2) 183-193
    CrossrefPubMedGoogle Scholar
  • 39 Lindh-Astrand L, Brynhildsen J, Hoffman M, Hammar M. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study.  Menopause. 2009;  16(6) 1213-1217
    CrossrefPubMedGoogle Scholar
  • 40 Haskell S G, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?.  Menopause. 2009;  16(3) 494-499
    CrossrefPubMedGoogle Scholar
  • 41 Beatty M N, Blumenthal P D. The levonorgestrel-releasing intrauterine system: safety, efficacy, and patient acceptability.  Ther Clin Risk Manag. 2009;  5(3) 561-574
    PubMedGoogle Scholar
  • 42 Raudaskoski T, Tapanainen J, Tomás E et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.  BJOG. 2002;  109(2) 136-144
    PubMedGoogle Scholar
  • 43 Backman T, Rauramo I, Jaakkola K et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer.  Obstet Gynecol. 2005;  106(4) 813-817
    CrossrefPubMedGoogle Scholar
  • 44 Lyytinen H K, Dyba T, Ylikorkala O, Pukkala E I. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well.  Int J Cancer. 2010;  126(2) 483-489
    CrossrefPubMedGoogle Scholar
  • 45 Oskay U Y, Beji N K, Yalcin O. A study on urogenital complaints of postmenopausal women aged 50 and over.  Acta Obstet Gynecol Scand. 2005;  84(1) 72-78
    CrossrefPubMedGoogle Scholar
  • 46 Rees M, Stevenson J, Hope S. Management of the Menopause. 5th ed. Leeds, United Kingdom; Royal Society of Medicine Press 2009
    PubMedGoogle Scholar
  • 47 Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women.  Obstet Gynecol. 2002;  99(4) 556-562
    CrossrefPubMedGoogle Scholar
  • 48 Palacios S. Managing urogenital atrophy.  Maturitas. 2009;  63(4) 315-318
    CrossrefPubMedGoogle Scholar
  • 49 Chervenak J. Bioidentical hormones for maturing women.  Maturitas. 2009;  64(2) 86-89
    CrossrefPubMedGoogle Scholar
  • 50 Gebbie A, Rees M. Post-reproductive gynaecology. In: Models of Care in Women's Health. London, United Kingdom; RCOG Press 2009: 81-88
    PubMedGoogle Scholar

Margaret ReesD.Phil. 

Women's Centre, John Radcliffe Hospital

Oxford OX3 9DU, United Kingdom

Email: margaret.rees@obs-gyn.ox.ac.uk

      >